BIOMARCADORES PARA DIAGNÓSTICO DE ENFERMEDAD INFLAMATORIA INTESTINAL

VolverVolver

Resultados 55 resultados LastUpdate Última actualización 29/09/2020 [21:56:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



previousPage Página2 de 3 nextPage   por página


Application of gene Bmal1 in preparation of product for detecting inflammatory bowel diseases

NºPublicación: CN111304316A 19/06/2020

Solicitante:

UNIV SUZHOU

Resumen de: CN111304316A

The invention discloses application of a gene Bmal1 in preparation of a product for detecting and treating inflammatory bowel diseases, and belongs to the technical field of biomedicine. The inventiondiscloses the application of the gene Bmal1 in the preparation of the product for detecting and treating the inflammatory bowel diseases. The invention discovers, from an aspect of intestinal epithelial lymphocytes, that a certain Breg cell for highly expressing PDL1 is capable of inhibiting enteritis and cannot be regulated and controlled due to biological clock anomaly, and then, occurrence anddevelopment of the enteritis are promoted. The invention further illuminates a molecular mechanism, for regulating and controlling the Breg cell, of the gene Bmal1, so that more bases are provided for research and development of drugs targeting the gene Bmal1 and treatment of clinical inflammatory bowel diseases.

traducir

MARKERS FOR DISEASE AND DISEASE EXTENT IN INFLAMMATORY BOWEL DISEASE

NºPublicación: US2020191803A1 18/06/2020

Solicitante:

UNIV OTTAWA [CA]

CA_3067062_A1

Resumen de: US2020191803A1

A method for determining a presence of inflammatory bowel disease in a subject. The method involves providing a gut sample obtained from a subject; measuring a level in said gut sample of one or more proteins, wherein said one or more proteins comprises at least one of: leukotriene A-4 hydrolase, catalase, transketolase, thioredoxin domain containing protein 17, vasodilator-stimulated phosphoprotein and thymosin beta-10; and comparing said measured level of each of said one or more proteins to a corresponding protein level for a normal subject. A method for determining a presence of pancolitis in a subject with ulcerative colitis is also provided.

traducir

MITIGATION AND REVERSAL OF FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION AND RELATED SIGNALING PATHWAYS

NºPublicación: US2020190203A1 18/06/2020

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

JP_2020033379_A

Resumen de: US2020190203A1

The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.

traducir

Application of PFOR protein specific IgA antibody as ulcerative colitis diagnostic marker

NºPublicación: CN111273038A 12/06/2020

Solicitante:

LI MING
WANG KAIRUO

Resumen de: CN111273038A

The invention provides application of a PFOR protein specific IgA antibody as an ulcerative colitis diagnostic marker, and belongs to the technical field of disease diagnosis. The method comprises thefollowing steps: screening a clostridium pullulans surface antigen, cloning, expressing and purifying the PFOR protein, and detecting the PFOR protein specific IgA antibody in the excrement of a patient according to an ELISA experimental principle. Research finds that compared with healthy people, the PFOR protein specific IgA antibody in excrement of patients with ulcerative colitis is obviouslyincreased and has significant difference. Therefore, the a PFOR protein specific IgA antibody can be used as a diagnostic marker for ulcerative colitis, so that clinical diagnosis and treatment and curative effect evaluation are facilitated, and the PFOR protein specific IgA antibody has good practical application value.

traducir

DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES

NºPublicación: JP2020091296A 11/06/2020

Solicitante:

DYAX CORP

AU_2020200423_A1

Resumen de: JP2020091296A

To provide methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis.SOLUTION: A method of diagnosing an autoimmune disease in a subject is provided, the method comprising: providing a biological sample of a subject suspected of having the autoimmune disease; measuring a level of cleaved high molecular weight kininogen (HMWK) in the biological sample; and identifying the subject as having or being at risk of developing the autoimmune disease if the level of cleaved HMWK in the biological sample is elevated as compared to that in a control sample.SELECTED DRAWING: Figure 1

traducir

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE

NºPublicación: US2020181244A1 11/06/2020

Solicitante:

CORIXA CORP [US]

US_2018362622_A1

Resumen de: US2020181244A1

Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.

traducir

METHOD OF DIAGNOSING A DYSBIOSIS

NºPublicación: US2020181674A1 11/06/2020

Solicitante:

SMARTDNA PTY LTD [AU]

JP_2020527055_A

Resumen de: US2020181674A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).

traducir

LACTIC ACID BACTERIUM OF SPECIES LACTOBACILLUS PLANTARUM ISOLATED FROM CRUCIAN CARP SUSHI AND METHOD FOR SCREENING SAME

NºPublicación: WO2020116365A1 11/06/2020

Solicitante:

NIPPON SUISAN KAISHA LTD [JP]

Resumen de: WO2020116365A1

[Problem] To provide a novel lactic acid bacterium having a high functionality that is isolated from crucian carp sushi. [Solution] Provided is a lactic acid bacterium belonging to the species Lactobacillus plantarum, which is isolated from crucian carp sushi and has at least one effect selected from the group consisting of effects of inhibiting viral infection, enhancing NK activity, reducing lipids, lowering blood neutral fat level and improving bowel movement. Also provided is a lactic acid bacterium that is Lactobacillus plantarum subsp. plantarum FS-1C strain.

traducir

BIOMARKERS FOR ASSESSING THE RESPONSE STATUS FOR TREATMENT OF INFLAMMATORY CONDITION OR DISEASE AFFECTING THE DIGESTIVE TRACT SUCH AS INFLAMMATORY BOWEL DISEASE IN HUMAN PATIENTS

NºPublicación: US2020181706A1 11/06/2020

Solicitante:

OSE IMMUNOTHERAPEUTICS [FR]
CT HOSPITALIER UNIVERSITAIRE NANTES [FR]

WO_2019025624_A1

Resumen de: US2020181706A1

The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TNFalpha agents, for treatment with anti-α4β7 agents or with both anti-TNFalpha agent and anti-α4β7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-α4β7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease. The invention describes a method of in vitro assessing whether a treatment with anti-TNFalpha agent or with anti-α4β7 agent may be useful in a human patient suffering from inflammatory condition or disease, in particular when said condition or disease is a chronic and/or relapsing one, particularly a gastrointestinal, more particularly intestinal, inflammatory condition or disease which is eligible for treatment with anti-TNFalpha agent or respectively with anti-α4β7 agent. In a specific embodiment the method is suitable to assess whether such patient would be non-responsive to treatment with such anti-TNFalpha agent or respectively with anti-α4β7 agent and comprising determining a molecular signature in a biological sample previously obtained from said human patient.

traducir

ASSESSMENT AND MONITORING OF MUCOSAL HEALING IN CHILDREN AND ADULTS WITH CROHN'S DISEASE

NºPublicación: WO2020117795A1 11/06/2020

Solicitante:

PROMETHEUS BIOSCIENCES INC [US]

Resumen de: WO2020117795A1

Provided are methods for assessing or monitoring mucosal healing in an adult or pediatric patient with Crohn's Disease (CD). Some embodiments include receiving or detecting levels of biomarkers. In some embodiments, the biomarkers include Ang1, Ang2, CEACAM1, VCAM1, TGFα, CRP, SAA1, MMP-1, MMP-2, MMP-3, MMP-9, EMMPRIN, or IL-7. Some embodiments include applying a mathematical algorithm to the biomarker levels to produce a Endoscopic Healing Index (EHI) score for the adult or pediatric patient.

traducir

METHODS OF STRATIFYING AND TREATING A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS

NºPublicación: WO2020113116A1 04/06/2020

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

Resumen de: WO2020113116A1

Described herein are methods and systems for identifying subpopulations of patients having Crohn ́s disease, including populations at risk of developing structuring or other severe disease, and populations susceptible to success or failure with surgical intervention. Further provided are therapies useful for treating subpopulations of patients having Crohn ́s disease.

traducir

METHODS AND USES OF INFLAMMATORY BOWEL DISEASE BIOMARKERS

NºPublicación: CN111212851A 29/05/2020

Solicitante:

UNIV WASHINGTON

AU_2018304283_A1

Resumen de: CN111212851A

Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1(PAI-1) inhibitor or tissue plasminogen activator (tPA).

traducir

METHODS AND USES OF INFLAMMATORY BOWEL DISEASE BIOMARKERS

NºPublicación: US2020165677A1 28/05/2020

Solicitante:

STAPPENBECK THADDEUS [US]
KAIKO GERARD [US]
LIU TA CHIANG [US]

Resumen de: US2020165677A1

Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1 (PAI-1) inhibitor or tissue plasminogen activator (tPA).

traducir

PREDICTING A TREATMENT RESPONSE IN INFLAMMATORY BOWEL DISEASE

NºPublicación: WO2020104705A2 28/05/2020

Solicitante:

UNIV LEUVEN KATH [BE]

Resumen de: WO2020104705A2

In general the present invention concerns a method for predicting the therapeutic outcome of a treatment of in inflammatory bowel disease for anti-TNF agents, anti- α4β7-intcgrin agents and/or anti- IL-12/23 agents. The method defines which the agents are likely to provide the best healing effect for a particular patients affected by an inflammatory bowel disease. In particular the method predicts the therapeutic outcome of a treatment of anti-TNF agents in inflammatory bowel disease.

traducir

USE OF BACTERIAL EXTRACELLULAR VESICLES AS A BIOMARKER FOR INTESTINAL BARRIER PERMEABILITY AND MICROBIAL DYSBIOSIS

NºPublicación: WO2020104577A1 28/05/2020

Solicitante:

UNIV GENT [BE]

Resumen de: WO2020104577A1

The present invention relates to a method of analyzing a biofluid of a subject for the presence of bacterial extracellular vesicles (EV), said method comprising the steps of a) extracting bacterial EV from said biofluid, b) analyzing said bacterial EV-extracted molecular patterns for the presence of a disease marker, wherein said disease marker is a disease-specific molecular pattern of said subject; and said subject comprising patients diagnosed with HIV, IBD or cancer or said subject receiving a treatment.

traducir

CAPTURING CROWD WISDOM IN INDIVIDUALIZED TREATMENT PLANS

NºPublicación: US2020168315A1 28/05/2020

Solicitante:

VIVANTE HEALTH INC [US]

Resumen de: US2020168315A1

Embodiments of the invention include systems and methods for capturing crowd wisdom to be tested for individualized treatment plans. These systems and methods include data mining crowd sourced health related information and unstructured medical narratives and storytelling to identify treatment plans and general techniques that individuals with chronic diseases/symptoms, including but not limited to IBD and other immune invisible neglected and stigmatized diseases, use to improve their general health and wellbeing. A system for testing the treatments effectiveness in a population and then in an individual is also disclosed.

traducir

METHODS AND USES OF INFLAMMATORY BOWEL DISEASE BIOMARKERS

NºPublicación: EP3655433A1 27/05/2020

Solicitante:

UNIV WASHINGTON [US]
STAPPENBECK THADDEUS [US]
KAIKO GERARD [US]
LIU TA CHIANG [US]

CN_111212851_A

Resumen de: WO2019018571A1

Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1(PAI-1) inhibitor or tissue plasminogen activator (tPA).

traducir

Human thymus stromal lymphopoietin monoclonal antibody and application thereof

NºPublicación: CN111196850A 26/05/2020

Solicitante:

BEIJING HUIZHI HEYUAN BIOTECHNOLOGY CO LTD

Resumen de: CN111196850A

The invention relates to the technical field of antibodies, and especially relates to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody can be specifically combined with hTSLP, has high affinity, and can effectively inhibit the combination of TSLP and a receptor thereof so as to inhibit activation of a downstream signal path and activation of immune cells by TSLP. The TSLP antibody has great significance in detection of the content of hTSLP and allergic asthma, and diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic nasosinusitis, eosinophilic granulocytic esophagitis, allergic conjunctivitis, inflammatory bowel disease or atopic dermatitis.

traducir

CIRCULATING FIBROBLAST ACTIVATION PROTEIN AS BIOMARKER FOR THE DIAGNOSIS OF AN INFLAMMATORY BOWEL DISEASE

NºPublicación: WO2020099378A1 22/05/2020

Solicitante:

INTHENA S R L [IT]

Resumen de: WO2020099378A1

The present invention concerns the field of inflammatory bowel diseases, and in particular it relates to the use circulating fibroblast activation protein, as a biological marker for the diagnosis of Crohn's disease or Ulcerative colitis in a blood sample. In a further aspect, the present invention relates to a method for the diagnosis of an Inflammatory Bowel Disease such as Crohn's disease.

traducir

METHODS AND COMPOSITIONS FOR PREDICTION OF RESPONSE TO A THERAPY OF AN INFLAMMATORY BOWEL DISEASE

NºPublicación: WO2020102519A1 22/05/2020

Solicitante:

JANSSEN BIOTECH INC [US]

Resumen de: WO2020102519A1

Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.

traducir

METHODS OF TREATING AND DIAGNOSING IBD ASSOCIATED WITH R. GNAVUS AND/OR R. GNAVUS GROUP IBD COLONIZATION

NºPublicación: US2020155617A1 21/05/2020

Solicitante:

BROAD INST INC [US]
MASSACHUSETTS GEN HOSPITAL [US]
HARVARD COLLEGE [US]

WO_2018195448_PA

Resumen de: US2020155617A1

This application provides for methods of treatment for IBD, especially in subjects who have R. gnavus species or R. gnavus group IBD strains as a component of their microbiome. The application also provides for methods of diagnosing IBD, as well as kits for use in the claimed methods.

traducir

Method of diagnosing a dysbiosis

NºPublicación: AU2020202974A1 21/05/2020

Solicitante:

SMARTDNA PTY LTD [AU]

JP_2020527055_A

Resumen de: AU2020202974A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).

traducir

INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO

NºPublicación: US2020157495A1 21/05/2020

Solicitante:

TRACT PHARMACEUTICALS INC [US]

WO_2018204913_PA

Resumen de: US2020157495A1

The present invention addresses IBD from the standpoint of mucosal stem cells cloned from defined regions of the gastrointestinal tract. In the case of pediatric Crohn's disease, for example, isolation of those stem cells according to the methods of the present invention reveals a pattern of inflammatory gene expression in stem cells from the terminal ileum and colon that is epigenetically maintained despite months of continuous cultivation in the absence of immune or stromal cells, or of intestinal microbes. Superimposed on this distributed inflammatory phenotype is a differentiation defect that profoundly and specifically alters the mucosal barrier properties of the terminal ileum. The co-existence of diseased and normal stem cells within the same endoscopic biopsies of Crohn's disease patients implicates an epigenetically enforced heterogeneity among mucosal stem cells in the dynamics of this condition.

traducir

METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: US2020149087A1 14/05/2020

Solicitante:

MEHARRY MEDICAL COLLEGE [US]

CN_110719960_A

Resumen de: US2020149087A1

Methods and materials are disclosed for testing biomarkers in a subject suffering from inflammatory bowel disease (IBD) are described herein. Such detection can be useful for diagnosing and treating ulcerative colitis (UC) and Crohn's disease (CD), two forms of IBD that are otherwise difficult to distinguish. The method includes measuring the level of one or more of several biomarkers, including HD5 or MMP-7, which are expressed differentially in patents with UC and CD. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.

traducir

DIAGNOSIS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE

Nº publicación: US2020149110A1 14/05/2020

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

US_2015259748_A1

Resumen de: US2020149110A1

This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.

traducir

previousPage Página2 de 3 nextPage por página

punteroimgVolver